Anrukinzumab
Anrukinzumab Basic information
- Product Name:
- Anrukinzumab
- Synonyms:
-
- Anrukinzumab
- Research Grade Anrukinzumab
- Anrukinzumab (anti-IL-13)
- CAS:
- 910649-32-0
- MW:
- 0
- Mol File:
- Mol File
Anrukinzumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Anrukinzumab Usage And Synthesis
Uses
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma[1][2][3].
in vivo
Anrukinzumab (IMA-638; 10 mg/kg; intravenous infusion; single) reduces lung inflammation in cynomolgus monkey model of lung inflammation[1].
| Animal Model: | Adult male cynomolgus monkeys (6 to 10 kg; cynomolgus monkey model of lung inflammation)[1]. |
| Dosage: | 10 mg/kg |
| Administration: | Intravenous infusion; single |
| Result: | Reduced total BAL cell count, eosinophil number, and neutrophil number. Reduced the levels of eotaxin and RANTES in BAL fluid. |
References
[1] Bree A, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007 May;119(5):1251-7. DOI:10.1016/j.jaci.2007.02.009
[2] Reinisch W, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015 Jun;64(6):894-900. DOI:10.1136/gutjnl-2014-308337
[3] Elias JA, et al. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med. 2011 Apr 15;183(8):957-8. DOI:10.1164/rccm.201101-0080ED
AnrukinzumabSupplier
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com